For Research Use Only — Not for human or veterinary use.

Education

BPC-157: The Complete Research Guide

A research overview of the gastric-derived pentadecapeptide BPC-157, its proposed VEGFR2/angiogenesis and growth-hormone-receptor mechanisms, and the tissue-repair, GI, and neurological research domains where it has been studied.

BPC-157
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.

Key Takeaways

  • BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of a protective protein identified in human gastric juice.[1]
  • One proposed mechanism involves upregulation of VEGFR2 (a receptor driving new blood vessel growth) and activation of the downstream Akt-eNOS pathway in endothelial cell research models.[2]
  • A separate mechanism reported in tendon fibroblast models involves increased growth hormone receptor expression alongside enhanced cell migration.[4]
  • Reviews describe BPC-157 across multiple soft-tissue injury research models, including tendon, ligament, and muscle healing markers.[3]
  • Its original research context was gastrointestinal protection, including inflammatory bowel disease trial models.[1]
  • A separate literature strand describes BPC-157's proposed role in brain-gut axis signaling, extending studied research domains into neurological research models.[5]

What It Is

BPC-157 (short for "Body Protection Compound-157") is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of a naturally occurring protein detected in human gastric juice. It was first characterized within a Croatian gastroprotection research program led by Sikiric and colleagues, and has since become one of the most frequently referenced compounds in tissue-repair peptide literature, often used as a comparison standard in study design.[1]

Mechanism & Pathway

Two overlapping mechanisms appear across the BPC-157 literature. The first centers on VEGFR2 (vascular endothelial growth factor receptor 2) — a receptor that drives new blood vessel growth. BPC-157 has been reported to upregulate VEGFR2 expression and promote its internalization in vascular endothelial cell models, activating the downstream Akt-eNOS signaling pathway and increasing nitric oxide production.[2] The second mechanism, studied in tendon fibroblast models, involves increased growth hormone receptor expression alongside enhanced cell migration and stress resistance — a distinct pathway from the angiogenesis mechanism above, though overlapping in downstream tissue-repair effects.[4]

Research Domains

  • Musculoskeletal & tendon healing research — reviews describe BPC-157 across multiple soft-tissue injury research models, citing accelerated healing markers in tendon, ligament, and muscle research contexts.[3]
  • Vascular & angiogenesis research — endothelial cell studies report VEGFR2 upregulation and internalization alongside Akt-eNOS pathway activation and increased nitric oxide production.[2]
  • Tendon fibroblast research — in vitro tendon fibroblast models report increased growth hormone receptor expression together with enhanced fibroblast migration.[4]
  • Gastrointestinal protection research — BPC-157's original research context, including trial models related to inflammatory bowel disease and gastric mucosal protection.[1]
  • Brain-gut axis research — a separate review literature strand discusses BPC-157 in the context of brain-gut and gut-brain axis signaling, extending studied research domains into neurological research models.[5]

Comparative Notes

BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4) in combined-compound tissue-repair research, and is available in this catalog both as a standalone vial and blended with TB-500. Mechanistically the two differ: TB-500 is primarily studied for actin regulation affecting cell migration, while BPC-157's most-reported pathways run through VEGFR2/angiogenesis and growth-hormone-receptor signaling described above.

BPC-157 product page → · BPC-157 & TB-500 product page →

Certificate of Analysis: What to Look For

A Certificate of Analysis for a BPC-157 research vial should report, at minimum: confirmed amino acid sequence (typically via mass spectrometry) and net peptide content. Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.

References

  1. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, Klicek R, Radic B, Keller N, Sipos K, Jakir A, Udovicic M, Tonkic A, Kokic N, Turkovic B, Mise S, Anic T (2006). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. PMID: 17186181
  2. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VHS, Pang JHS (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berl). PMID: 27847966
  3. Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. PMID: 30915550
  4. Chang CH, Tsai WC, Hsu YH, Pang JHS (2014). Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. PMID: 25415472
  5. Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, Grgic T, Strbe S, Zukanovic G, Crvenkovic D, Madzarac G, Rukavina I, Sucic M, Baric M, Starcevic N, Krstonijevic Z, Bencic ML, Filipcic I, Rokotov DS, Vlainic J (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. PMID: 27138887

FAQ

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a protective protein identified in human gastric juice, first characterized within gastroprotection research.[1]

Two main mechanisms appear in the literature: VEGFR2 upregulation with downstream Akt-eNOS pathway activation in vascular research models, and growth hormone receptor upregulation in tendon fibroblast models.[2][4]

Yes. Beyond musculoskeletal and vascular research, a separate literature strand discusses BPC-157 in gastrointestinal protection and brain-gut axis research contexts.[1][5]

The two are mechanistically distinct: TB-500 is primarily studied for actin regulation affecting cell migration, while BPC-157 is most associated with VEGFR2/angiogenesis and growth-hormone-receptor signaling. They are frequently studied together in combined-compound tissue-repair research.

A COA for a BPC-157 research vial should report confirmed amino acid sequence and net peptide content, consistent with the documentation standard used across this catalog.

No. BPC-157 is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance.

Related Guides